Search Result

Results for "

METTL3 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	METTL3 (25) Apoptosis (9) Bcl-2 Family (2) c-Myc (1) Caspase (1) Cytochrome P450 (1) DNA Methyltransferase (1) Endogenous Metabolite (4) Enterovirus (1) MDM-2/p53 (1) NF-κB (1) PROTACs (4) Reference Standards (1)
By Research Areas:	Cancer (23) Infection (1) Inflammation/Immunology (2) Metabolic Disease (4)
Oligonucleotides:	Adenosine (1) Nucleoside Analogs (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: METTL3 RNA MTase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134836

STM2457 Maximum Cited Publications 104 Publications Verification	Apoptosis METTL3	Cancer
STM2457 is a first-in-class, highly potent, selective and orally active *METTL3* inhibitor with an IC₅₀ of 16.9 nM. STM2457 can be used for the research of acute myeloid leukaemia (AML) .

HY-19528

SAH 15+ Cited Publications SAH (S-Adenosylhomocysteine)	Endogenous Metabolite	Metabolic Disease
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-156677

STC-15 4 Publications Verification	METTL3	Cancer
STC-15 is an orally active RNA methyltransferase *METTL3* inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .

HY-156773

STM3006 2 Publications Verification	Apoptosis METTL3	Cancer
STM3006 is a highly potent, selective, and orally active inhibitor of *METTL3* (IC₅₀: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results .

HY-115717

UZH2 1 Publications Verification	METTL3	Cancer
UZH2 is a potent and selective *METTL3* inhibitor with an IC₅₀ value of 5 nM.

HY-160415

WD6305 2 Publications Verification	PROTACs Apoptosis METTL3	Cancer
WD6305 is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 has DC₅₀ values of 140 nM and 194 nM for *METTL3* and *METTL14, respectively. WD6305 inhibits* m ⁶A modification and proliferation of AML cells, and induces apoptosis. WD6305 has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))

HY-160415A

WD6305 TFA 2 Publications Verification	PROTACs Apoptosis METTL3	Cancer
WD6305 TFA is a potent and selective METTL3-METTL14 PROTAC degrader. WD6305 TFA has DC₅₀ values of 140 nM and 194 nM for *METTL3* and *METTL14, respectively. WD6305 TFA inhibits* m ⁶A modification and proliferation of AML cells, and induces apoptosis. WD6305 TFA has antitumor activity .(Pink: UZH2 (HY-115717); Black: Linker; Blue: VHL ligand (HY-150803))

HY-153625

STM2120 2 Publications Verification	METTL3	Cancer
STM2120 is a *METTL3-METTL14* inhibitor with an IC₅₀ of 64.5 μM .

HY-19528S

SAH-d4 SAH (S-Adenosylhomocysteine)-d₄	Endogenous Metabolite	Metabolic Disease
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-134673A

UZH1a 3 Publications Verification	Apoptosis	Cancer
UZH1a is a potent and selective *METTL3* inhibitor, with an IC₅₀ of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3 .

HY-P10387

RSM3 1 Publications Verification	METTL3 Apoptosis MDM-2/p53 NF-κB Caspase	Cancer
RSM3 is a *METTL3-METTL14* complex inhibitor with a K_d of 3.10 μM for the *METTL3-METTL14* complex. RSM3 reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer .

HY-174873

AF151	PROTACs METTL3 Apoptosis Bcl-2 Family	Cancer
AF151 is a METTL3 PROTAC degrader with the DC₅₀ of 0.43 μM in MOLM-13 cells. AF151 inhibits cell growth by significantly degrading *METTL3* protein and reducing m6A levels. AF151 can induce cell apoptosis and reduce the level of Bcl-2 protein. AF151 can be used for research on cancer such as acute myeloid leukemia (AML). (Pink: METTL3 Ligand (HY-174874); Blue: VHL Ligand (HY-125845); Black: Linker; VHL Ligand+Linker (HY-174875)) .

HY-134673

UZH1 3 Publications Verification	Apoptosis	Cancer
UZH1 is a racemate of UZH1a and UZH1b. UZH1a is a potent and selective *METTL3* inhibitor, with an IC₅₀ of 280 nM. UZH1b (IC₅₀=28 µM) is essentially inactive. UZH1 can be used for epitranscriptomic modulation of cellular processes. UZH1 has antitumor activity. UZH1 also can be used as a chemical probe for studying METTL3 .

HY-158404

METTL3-IN-8	METTL3	Inflammation/Immunology
METTL3-IN-8 (F039-0002) is a potent *METTL3* inhibitor. METTL3-IN-8 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-8 can be used Inflammatory bowel disease (IBD) research .

HY-168878

EP652	METTL3	Cancer
EP652 is a *METTL3* inhibitor and antitumor agent with IC₅₀ values of 2 nM, <10 nM, and 37 nM in SPA, intracellular, and ATPlite assays, respectively. EP652 exhibits high selectivity against 40 other methyltransferases and FTO, and possesses favorable pharmacokinetic parameters. EP652 reduces intracellular N ⁶-methyladenosine (m ⁶A) levels in mRNA. EP652 inhibits tumor growth and progression of both hematologic malignancies and solid tumors. EP652 can be used for the research of acute myeloid leukemia, ovarian cancer, non-small cell lung cancer, and hypopharyngeal squamous cell carcinoma .

HY-159604

METTL3-IN-9	METTL3	Cancer
METTL3-IN-9 (compound C3) is an inhibitor of methyltransferase-like *METTL3*, an RNA methyltransferase that catalyzes the N6-methyladenosine (m6A) modification of mRNA in eukaryotic cells .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

HY-148468

METTL3-IN-2	METTL3	Cancer
METTL3-IN-2 (compound 28) is a *METTL3* inhibitor with an IC₅₀ value of 6.1 nM. METTL3-IN-2 inhibits cell proliferation of Caov3 cancer cells .

HY-162930

PROTAC METTL3 degrader 1	PROTACs METTL3	Cancer
PROTAC METTL3 degrader 1 is a VHL-based PROTAC METTL3 degrader (DC₅₀: 220 nM in MOLM-13 cells). PROTAC METTL3 degrader 1 inhibits METTL3/14 complex with an IC₅₀ value of 341 nM. PROTAC METTL3 degrader 1 can be used for the research of acute myeloid leukemia and gastric cancer .

HY-P10387A

RSM3 TFA 1 Publications Verification	METTL3 Apoptosis	Cancer
RSM3 TFA is a *METTL3-METTL14* complex inhibitor with a K_d of 3.10 μM for the *METTL3-METTL14* complex. RSM3 TFA reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer .

HY-178446

METTL3-IN-11	METTL3 c-Myc Bcl-2 Family	Cancer
METTL3-IN-11 is an excellent, selective *METTL3* inhibitor (IC₅₀ = 45.31 nM). METTL3-IN-11 exhibits high selectivity towards METTL3 compared to DNMT1, EZH1, MLL1, and PRMT1. METTL3-IN-11 reduces the m6A level of total RNA in MOLM-13 and SKOV3 cells, induces cell apoptosis, and inhibits cell migration. METTL3-IN-11 can reduce the expression of m6A downstream target genes (c-MYC and BCL2). METTL3-IN-11 can be used for the study of ovarian cancer and acute myeloid leukemia .

HY-162082

METTL1-WDR4-IN-2	DNA Methyltransferase	Cancer
METTL1-WDR4-IN-2, an adenosine derivative, is a selective methyltransferase Like 1 (METTL1)-WDR4 inhibitor with an IC₅₀ of 41 μM. METTL1-WDR4-IN-2 shows selectivity against METTL3-14 (IC₅₀ of 958 μM) and METTL16 (IC₅₀ of 208 μM). METTL1-WDR4-IN-2 can be used for the study of cancer .

HY-148469

METTL3-IN-3	METTL3	Others
METTL3-IN-3 (compound 11) is a polyheterocyclic compound, acts as *METTL3* inhibitor .

HY-179239

METTL3-IN-12	METTL3	Cancer
METTL3-IN-12 (Compound 15) is a selective *METTL3* inhibitor with an IC₅₀ of 50 nM. METTL3-IN-12 exhibits significant anti-proliferative activity in various leukemia cell lines. METTL3-IN-12 can be used for research on leukemia .

HY-156759

METTL3-IN-5	METTL3	Cancer
METTL3-IN-5 (Compound 13) is a *METTL3* inhibitor. METTL3-IN-5 inhibits MOLM-13 growth with an IC₅₀ less than 2 μM. METTL3-IN-5 has weak hERG inhibitory activity (IC₅₀ >30 μM). METTL3-IN-5 can be used for AML research .

HY-158403

METTL3-IN-7	METTL3	Inflammation/Immunology
METTL3-IN-7 (7460-0250) is a potent *METTL3* inhibitor. METTL3-IN-7 strongly ameliorates Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis. METTL3-IN-7 can be used Inflammatory bowel disease (IBD) research .

HY-148467

METTL3-IN-1	METTL3	Others
METTL3-IN-1 (compound 23) is a polyheterocyclic compound, acts as *METTL3* inhibitor .

HY-134673B

UZH1b	METTL3	Others
UZH1b is an enantiomer of UZH1a (a METTL3 inhibitor). UZH1b is essentially inactive for METTL3 (IC₅₀=28 µM) .

HY-19528S2

SAH-13C10	Endogenous Metabolite	Metabolic Disease
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-154997

7OQL	METTL3	Cancer
7OQL (compound 54) is a selective *METTL3* inhibitor (IC₅₀=0.054 µM). 7OQL has the potential to be used in the study of cancer .

HY-151926

Antiviral agent 24	Enterovirus	Infection
Antiviral agent 24 is a potent antiviral agent with EC₅₀ values of 0.101, 19.9, 91.2 µM for EV71, CVA21, EV68, respectively. Antiviral agent 24 inhibits METTL3/METTL14 activity in a dose-dependent manner .

HY-181567

METTL3-IN-13	METTL3	Cancer
METTL3-IN-13 is a *METTL3* inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer .

HY-183186

EP102	METTL3 Cytochrome P450	Cancer
EP102 is an orally active, selective inhibitor of the *METTL3/METTL14* complex with an IC₅₀ of 2 nM. EP102 reduces intracellular N6-methyladenosine levels, inhibits cancer cell proliferation, and thereby suppresses tumor growth in mouse models. EP102 is applicable for the research of acute myeloid leukemia, ovarian solid tumors and advanced solid tumors .

Cat. No.	Product Name	Target	Research Area

HY-P10387

RSM3 1 Publications Verification	METTL3 Apoptosis MDM-2/p53 NF-κB Caspase	Cancer
RSM3 is a *METTL3-METTL14* complex inhibitor with a K_d of 3.10 μM for the *METTL3-METTL14* complex. RSM3 reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 is applicable to the research of preeclampsia and cancer .

HY-P10387A

RSM3 TFA 1 Publications Verification	METTL3 Apoptosis	Cancer
RSM3 TFA is a *METTL3-METTL14* complex inhibitor with a K_d of 3.10 μM for the *METTL3-METTL14* complex. RSM3 TFA reduces the m ⁶A modification level of SLC31A1 and the global RNA methylation level. RSM3 TFA upregulates programmed cell death-related genes, enhances cell apoptosis, inhibits pro-cancer signals and suppresses tumor growth. RSM3 TFA is applicable to the research of preeclampsia and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-19528

SAH 15+ Cited Publications SAH (S-Adenosylhomocysteine)	Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Disease markers Metabolic Disease Amino acids Nervous System Disorder Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

HY-19528R

SAH (Standard) SAH (S-Adenosylhomocysteine) (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Disease markers Amino acids Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .

Cat. No.	Product Name	Chemical Structure

HY-19528S

SAH-d4
SAH-d₄ is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

HY-19528S2

SAH-13C10
SAH- ¹³C₁₀ is the ¹³C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 μM .

Cat. No.	Product Name		Classification

HY-19528

SAH 15+ Cited Publications SAH (S-Adenosylhomocysteine)		Nucleoside Analogs Adenosine
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC₅₀ of 0.9 µM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

METTL3 inhibitor

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products